ABSTRACT
OBJECTIVES: Our objective was to evaluate the efficacy and tolerability of bosentan in patients with systemic sclerosis (SSc) who develop ulcers and healed ulcers. We also wanted to analyse the effect of bosentan on other skin and general outcome measurements. METHODS: In the present prospective, observational, non-controlled study, we followed all patients with SSc who started treatment with bosentan for ischaemic ulcers and healed ulcers from January 2003 to June 2006 in our centre. We recorded skin and general outcome measurements at baseline and at 6 months. RESULTS: Fifteen patients were included. After a median follow-up of 24.7 months (range: 4-36), there was a significant decrease in the number of ulcers. A trend towards efficacy was seen in the number of healed ulcers and in the severity of ulcers. No significant effect was seen in other skin and general outcome measurements. Toxicity related to bosentan included mild transitory events and one toxic hepatitis. CONCLUSION: Bosentan may be a safe long-term alternative for treating the recurrence of skin ulcers and healed ulcers in SSc patients.
Subject(s)
Scleroderma, Systemic/drug therapy , Skin Ulcer/drug therapy , Sulfonamides/therapeutic use , Adolescent , Adult , Aged , Bosentan , Child , Endothelin Receptor Antagonists , Female , Humans , Male , Middle Aged , Prospective Studies , Scleroderma, Systemic/complications , Severity of Illness Index , Skin Ulcer/etiology , Sulfonamides/adverse effects , Treatment OutcomeABSTRACT
Este artículo pretende mostrar diversos protocolos de actuación ante un paciente que se presenta en nuestra consulta con dolor articular de inicio reciente, insistiendo en la detección de aquellos signos de alarma ante los cuales un diagnóstico precoz determina una disminución de la morbimortalidad (AU)
